

# Safety Notice

## Medical Devices

### Philips Ventilators

Trilogy 100, Trilogy 200, Garbin Plus, Aeris, LifeVent, A-Series BiPAP Hybrid A30, A-Series BiPAP V30 Auto, A-Series BiPAP A40, A-Series BiPAP A30



### Philips Sleep and Respiratory care devices

E30  
 DreamStation ASV  
 DreamStation ST, AVAPS  
 SystemOne ASV4  
 C-Series ASV  
 C-Series S/T and AVAPS  
 OmniLab Advanced+  
 SystemOne (Q-Series)  
 DreamStation  
 DreamStation Go  
 Dorma 400  
 Dorma 500  
 REMstar SE Auto



**Priority 1 – For Immediate Action**

HPRA Safety Notice: SN2021(05 Version 2)

Update Issued: 20<sup>th</sup> July 2021

MANUFACTURER / SUPPLIER	HPRA CASE REFERENCE
Philips Respironics	V46723

## ISSUE

The Health Products Regulatory Authority (HPRA) is issuing this Safety Notice to raise awareness of two issues identified with certain Philips Respironics ventilators, sleep and respiratory care devices (also known as 'CPAPs' or 'BiPAPs') manufactured before 26<sup>th</sup> April 2021.

Philips has advised that the two issues are due to the potential that polyester-based polyurethane (PE-PUR) sound abatement foam used in these devices:

- 1) may degrade into particles which may enter the device's air pathway and be ingested or inhaled by the user and,
- 2) may emit certain chemicals.

A list of all affected models and further information on the issues is available in the accompanying field safety notices (FSNs) issued by Philips. Where certain device models may have been previously marketed under alternate names (eg. SystemOne REMstar) please contact Philips or your provider to establish if your device is within the scope of this issue. It is important to note that the FSNs advise not stopping or changing your prescribed therapy without first consulting your doctor.

## ACTION OR RECOMMENDATIONS

### The HPRA advises users to:

1. Identify whether your device is one of the impacted models listed in the accompanying FSNs.

Based on the current information supplied by Philips, the Health Service Executive (HSE) recommends that all patients and device users continue to use their device as prescribed until a replacement device is supplied or the device repaired. Further details are available on the HSE website

<https://www.hse.ie/eng/services/news/newsfeatures/advice-philips-respironics-devices/>

2. Register your device at <https://www.philips.ie/healthcare/e/sleep/communications/src-update>  
Call 1800 851 241 if you cannot visit the website or do not have internet access.
3. Report any adverse incidents associated with these devices to the manufacturer and to the HPRA.

### The HPRA advises that healthcare professionals:

1. Refer to the accompanying FSNs for further information in relation to this issue.
2. Acknowledge receipt of the FSNs if you have not already done so.
3. Refer to information provided by Philips for physicians and other medical care providers at <https://www.philips.ie/healthcare/e/sleep/communications/src-update/information-for-physicians-and-providers>
4. Report any adverse incidents associated with this device to the manufacturer and to the HPRA.

Note – This is an emerging issue, the HPRA is working with the HSE, hospital and community services to further assess this issue and the potential impact on patients in Ireland. As information becomes available, the up to date HSE advice will be published on their website <https://www.hse.ie/eng/services/news/newsfeatures/advice-philips-respironics-devices/>

The HPRA has also published a Special Topics webpage for this issue at <https://www.hpra.ie/homepage/medical-devices/special-topics/philips-sleep-and-respiratory-care-devices>

Suppliers are requested to forward a copy of this Safety Notice and the accompanying FSNs to all affected users and to any organisation / persons to which / whom these devices have been transferred.

TARGET GROUPS	
Users of affected devices and their carers Respiratory consultants General practitioners Community care managers Paediatricians Risk managers Supplies managers	Outpatient clinics Intensive Care Units Neonatal Intensive Care Units Nursing Homes Sleep Centres Rehabilitation Units

**BACKGROUND**

Philips Respironics has initiated a global field safety corrective action and issued the accompanying FSNs to notify device users of the two issues outlined above. As described in these notices, the manufacturer has identified a number of potential risks, which may have significant effects on the users of these devices in the long term, including potential risks related to exposure to carcinogens.

To date, Philips has received several global complaints regarding the presence of black debris/particles within the air pathway circuit (extending from the device outlet, humidifier, tubing, and mask). Philips also has received reports of headache, upper airway irritation, cough, chest pressure and sinus infection.

Philips has advised that they are deploying a permanent corrective action to address these issues. Further information on this corrective action and the status of the field action are available at: <https://www.philips.ie/healthcare/e/sleep/communications/src-update>

**MANUFACTURER / AUTHORISED REPRESENTATIVE / DISTRIBUTOR CONTACT INFORMATION**

Enquiries to the **manufacturer** should be addressed to:

Philips Respironics Inc, 312 Alvin Drive,	Telephone: 1800851241 E-mail: <a href="mailto:devicevigilanceuki@philips.com">devicevigilanceuki@philips.com</a>
--	---

New Kensington, 15068,  
USA

Website:  
<https://www.philips.ie/healthcare/e/sleep/communications/src-update>

Enquiries to the **authorised representative** should be addressed to:

Respironics Deutschland GmbH & Co. KG,  
Gewerbestr 17,  
Herrsching 82211, Germany

Telephone: 1800851241  
E-mail: [devicevigilanceuki@philips.com](mailto:devicevigilanceuki@philips.com)

Enquiries to the **distributors** should be addressed to:

**Air Liquide**

18 H Rosemount Business Park, Ballycoolin, Dublin 11

Telephone: 1800 740202 (Option 3)  
E-mail: [healthie@airliquide.ie](mailto:healthie@airliquide.ie)  
Website: [www.airliquide.ie](http://www.airliquide.ie)

**Direct Medical**

Suite 2 Gateway Centre, Monksland, Athlone, Co. Roscommon, N37 CD77

Telephone: 09064 90190  
E-mail: [patient.support@directmedical.ie](mailto:patient.support@directmedical.ie)

**Cardiac Services**

Unit 3a, Northern Cross Business Park, Finglas, Dublin 11, D11 WY11

Telephone: (01) 8307499  
E-mail: [recalls@cardiac-services.com](mailto:recalls@cardiac-services.com)

**BOC Healthcare**

Bluebell, Dublin 12

Telephone: 1800 22 02 02  
E-mail: [healthcareinfo.ie@boc.com](mailto:healthcareinfo.ie@boc.com)

**PAP Healthcare**

18 Laburnum Park, Model Farm Road, Cork.

Telephone: (021) 419 3009 (Option 4)  
E-mail: [support@paphealthcare.ie](mailto:support@paphealthcare.ie)

**HPR CONTACT INFORMATION**

All **adverse incidents** relating to a medical device should be reported to:

Health Products Regulatory Authority  
Kevin O'Malley House  
Earlsfort Centre  
Earlsfort Terrace  
Dublin 2

Telephone: +353-1-6764971  
E-mail: [devicesafety@hpra.ie](mailto:devicesafety@hpra.ie)  
Website: [www.hpra.ie](http://www.hpra.ie)